An eight- week randomized, double-blind, placebo-controlled, parallel group proof of concept study to assess the efficacy, safety and tolerability as well as the pharmacokinetic profile of oral solabegron (GW427353) 125mg and 50mg administered twice daily vs placebo in women with overactive bladder

Trial Profile

An eight- week randomized, double-blind, placebo-controlled, parallel group proof of concept study to assess the efficacy, safety and tolerability as well as the pharmacokinetic profile of oral solabegron (GW427353) 125mg and 50mg administered twice daily vs placebo in women with overactive bladder

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2012

At a glance

  • Drugs Solabegron (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Feb 2012 Results presented at the 27th Congress of the European Association of Urology.
    • 25 Mar 2011 Positive top-line results reported in a AltheRx media release.
    • 18 Jan 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top